IP Verse

Vertex Pharmaceuticals patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest patents of Vertex Pharmaceuticals opposed by its competitors

Explore Vertex Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 14, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4069691
Sep 18, 2024Substituted Tetrahydrofurans As Modulators Of Sodium Channels1
EP2464337
Jun 26, 2024Pharmaceutical Composition And Administrations Thereof1
EP2914248
Oct 18, 2023Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases1
EP3352757
Aug 16, 2023Administration Of Deuterated Cftr Potentiators1
EP3925607
Jun 28, 2023Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases1
EP3880197
Feb 22, 2023Methods Of Treatment For Cystic Fibrosis2
EP3752510
Dec 7, 2022Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making Them1
EP3798214
Sep 14, 2022Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1
EP3345625
Dec 9, 2020Pharmaceutical Composition And Administrations Thereof3
EP3203840
Aug 5, 2020Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1

Top competitors of Vertex Pharmaceuticals

Top competitors of Vertex Pharmaceuticals based on patent oppositions.